Shen Cheng, Ph.D.

Research Scientist I

Shen joined Metrum Research Group after receiving his Ph.D. in Experimental and Clinical Pharmacology from the University of Minnesota in 2021. His thesis work used a pharmacometric modeling approach to investigate the impact of pharmacogenetic differences in drug-drug interactions (DDIs).

Recent publications by this scientist

Population Pharmacokinetic (PK) and Exposure-Response (ER) Analysis of Empagliflozin in Pediatric Patients with Type 2 Diabetes Mellitus (T2DM)

November 15, 2023

Presented at ACoP14. Empagliflozin, effective for type 2 diabetes in adults and children, underwent Study 1218.91 to assess its safety and efficacy over 26 weeks (with potential extension to 52 weeks) in children and adolescents. Using pediatric data from this study, researchers re-evaluated empagliflozin’s models in a Bayesian framework. Results showed similar drug exposure between children and adults at a 10 mg dose. At week 26, pediatric patients displayed a slightly larger but variable decrease in A1c compared to adults. This Bayesian method allowed insights into empagliflozin’s effects in children, drawing from knowledge gained in adult studies.

Download PDF

simpar: an R Package for Parameter Uncertainty Simulations in Pharmacometric Modeling

November 15, 2023

Presented at ACoP14. This project is dedicated to integrating parameter uncertainty into pharmacometric simulations, which plays a crucial role in making informed decisions in drug development. Initially, the metrumrg package in R was instrumental for simulating both fixed and random effect parameters. However, this package has since been deprecated. Consequently, the primary objective was to create a new R package named simpar. This new package aimed to retain the essential functionalities of metrumrg while expanding its capabilities. The overarching goal was to significantly enhance the support for incorporating parameter uncertainty into pharmacometric simulations, thereby aiding more comprehensive and accurate decision-making processes in this field.

Download PDF

Population Pharmacokinetic and Exposure-Response Analysis of Linagliptin in Pediatric Patients with Type 2 Diabetes Mellitus

November 15, 2023

Presented at ACoP14. This study assessed linagliptin’s effectiveness and safety in children and adolescents with type 2 diabetes over 26 weeks, potentially extending to 52 weeks. The study re-evaluated models developed for adults and adolescents to understand linagliptin’s impact on pediatric patients’ HbA1c levels. Results indicated slightly higher and more varied linagliptin exposure in children compared to adults at a 5 mg dose. Although pediatric patients had a smaller and variable HbA1c reduction versus adults at week 26, the Bayesian approach helped characterize linagliptin’s effects in children based on limited data, borrowing insights from adult studies.

Download PDF